Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-073317
Filing Date
2026-02-26
Accepted
2026-02-26 06:39:42
Documents
71
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K nuvl-20251231.htm   iXBRL 10-K 3501689
2 EX-19.1 nuvl-ex19_1.htm EX-19.1 267539
3 EX-23.1 nuvl-ex23_1.htm EX-23.1 3127
4 EX-31.1 nuvl-ex31_1.htm EX-31.1 17588
5 EX-31.2 nuvl-ex31_2.htm EX-31.2 17846
6 EX-32.1 nuvl-ex32_1.htm EX-32.1 8564
7 EX-32.2 nuvl-ex32_2.htm EX-32.2 9037
8 GRAPHIC img123481027_0.jpg GRAPHIC 173738
9 GRAPHIC img123481027_1.gif GRAPHIC 388604
10 GRAPHIC img123481027_2.gif GRAPHIC 1351521
11 GRAPHIC img123481027_3.jpg GRAPHIC 60933
  Complete submission text file 0001193125-26-073317.txt   16605174

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nuvl-20251231.xsd EX-101.SCH 1302938
74 EXTRACTED XBRL INSTANCE DOCUMENT nuvl-20251231_htm.xml XML 1802570
Mailing Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 508-446-2272
Nuvalent, Inc. (Filer) CIK: 0001861560 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40671 | Film No.: 26681592
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)